Crossmark

Immune–epithelial–stromal networks define the cellular ecosystem of the small intestine in celiac disease

Crossref DOI link: https://doi.org/10.1038/s41590-025-02146-2

Published Online: 2025-05-06

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

FitzPatrick, Michael E. B. https://orcid.org/0000-0003-2365-2012
Antanaviciute, Agne

Dunstan, Melanie

Künnapuu, Karolina https://orcid.org/0000-0003-1267-0194
Trzupek, Dominik

Provine, Nicholas M. https://orcid.org/0000-0002-9694-2216
Dooley, Kyla

Zhang, Jia-Yuan

Irwin, Sophie L.

Garner, Lucy C. https://orcid.org/0000-0002-6461-252X
Pernes, Jane I.

Ferreira, Ricardo C. https://orcid.org/0000-0001-5733-3285
Sasson, Sarah C. https://orcid.org/0000-0002-5329-9072
Aschenbrenner, Dominik https://orcid.org/0000-0001-7580-2567
Agarwal, Devika

Rodrigues, Astor

Howarth, Lucy

Brain, Oliver

Ruane, Darren

Soilleux, Elizabeth https://orcid.org/0000-0002-4032-7249
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
Dendrou, Calliope A. https://orcid.org/0000-0003-1179-4021
Simmons, Alison

Uhlig, Holm H. https://orcid.org/0000-0002-6111-7355
Todd, John A.

Klenerman, Paul https://orcid.org/0000-0003-4307-9161
Funding

Funding for this research was provided by:

Academy of Medical Sciences

Beyond Celiac, Coeliac UK

Oxford-BMS Translational Fellowship Scheme

Wellcome Trust (WSSS 211276/Z/18/Z & 218597/Z/19/Z, WSSS 211276/Z/18/Z & 218597/Z/19/Z), WSSS 211276/Z/18/Z & 218597/Z/19/Z, WSSS 211276/Z/18/Z & 218597/Z/19/Z, 222426/Z/21/Z))

Johnson and Johnson Innovative Medicine via the Cartography Consortium

JDRF/Wellcome Diabetes and Inflammation Laboratory Strategic Award
License Information

Text and Data Mining valid from 2025-05-06

Version of Record valid from 2025-05-06
More Information

Article History

Received: 10 December 2023

Accepted: 25 March 2025

First Online: 6 May 2025

Competing interests

: M.E.B.F. consults for Takeda Pharmaceuticals. N.M.P. has consulted for Infinitopes. D.R. is an employee of Janssen Immunology. D. Aschenbrenner is an employee of Novartis Institute of BioMedical Research. S.A.T. is a scientific advisory board member of ForeSite Labs, OMass Therapeutics, Qiagen and Xaira Therapeutics, a cofounder and equity holder of TransitionBio and Ensocell Therapeutics, a non-executive director of 10x Genomics, and a part-time employee of GlaxoSmithKline. J.A.T. consults for GSK, Vesalius, Avammune, Azenta, Dasman Diabetes Institute and Immunocore. P.K. has consulted for AZ, Infinitopes and UCB, and received research funding from Immunocore, all on unrelated projects. The other authors declare no competing interests.

Document is current

Any future updates will be listed below